Overview

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

Status:
Completed

Trial end date:
2016-11-04

Target enrollment:

Participant gender:

Summary

The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade® (bortezomib), melphalan and prednisone (VMP).

Phase:

Phase 3

Details

Lead Sponsor:

Amgen
Onyx Therapeutics, Inc.

Treatments:

Bortezomib
Melphalan
Prednisone